Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study.
Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions.
NAD⁺ in aging, metabolism, and neurodegeneration.
Association Between Multiple Sclerosis and Erectile Dysfunction: A Nationwide Case-Control Study.
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
miRNA in multiple sclerosis: search for novel biomarkers.
Twin studies and the heritability of MS: a conclusion.
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
Simvastatin shows promise in treating progressive multiple sclerosis, study finds.
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
MS and NMO: Partners No More.
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases
Myelination of the nervous system: mechanisms and functions.
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Tocilizumab, MS, and NMOSD.
A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q).
Information on natalizumab (marketed as Tysabri)
Neuroprotective effects of riluzole in neurotrauma models: a review.
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.

Pages